Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21191243 | 0.77 | ALDH1A1 (0.34) | ALDH1A1CYP2D6HIF1A | |
| SCHEMBL21191168 | 0.76 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL22329135 | 0.73 | DPP4 (0.31) | DPP4DPP8DPP9 | |
| SCHEMBL20179863 | 0.73 | CYP2D6 (0.34) | ALDH1A1CYP2D6HIF1A | |
| SCHEMBL20179861 | 0.71 | ALDH1A1 (0.34) | ALDH1A1CYP2D6HIF1A | |
| SCHEMBL20179888 | 0.71 | DPP4 (0.32) | ALDH1A1DPP4DPP8DPP9CYP2D6 | |
| SCHEMBL22329083 | 0.71 | ALDH1A1 (0.33) | ALDH1A1CYP2D6HIF1A | |
| SCHEMBL21191217 | 0.68 | CYP2D6 (0.32) | CYP2D6HIF1A | |
| SCHEMBL21191148 | 0.68 | ALDH1A1 (0.33) | ALDH1A1CYP2D6HIF1A | |
| SCHEMBL21190945 | 0.68 | ALDH1A1 (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11166954-B2 | Dihydropyrimidine compound and preparation method and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-11-09 | — | — | US | disclosed |
| WO-2018090862-A1 | DIHYDROPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166954-B2 | Dihydropyrimidine compound and preparation method and use thereof | DPYD, DHPS, HPRT1 | ALDH1A1 260/4885DPP4 154/4885DPP8 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.